Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
With
Merck Sharp & Dohme LLC
Key eligibility criteria include:
* Newly diagnosed invasive breast cancer awaiting surgery or neoadjuvant (preoperative) treatment
* No use of hormone contraceptives or replacement therapy within 30 days prior to the diagnostic breast cancer biopsy (unless willing to have an additional biopsy prior to starting the study)
* No prior or current use of any therapy to treat the current breast cancer.
Age
18–any
Sex
FEMALE
Healthy volunteers
Not accepted
You may be eligible if
Stage I-III invasive breast cancer
Awaiting surgery or neoadjuvant treatment
ECOG performance status 0, 1 or 2
Adequate organ function
Prior use of hormone contraception or replacement therapy must have been discontinued at least 30 days prior to diagnostic biopsy (unless participant is willing to undergo an additional biopsy for the study)
You may not be if
Prior or current treatment of any kind for the current breast cancer
Current use of any other investigational drugs
Uncontrolled or active infection, congestive heart failure, cardiac arrythmia, or psychiatric illness
